Data from the Centers for Medicare & Medicaid Services (CMS) shows that 4.3 million Medicare beneficiaries, including 3.1 million Medicare Advantage drug plan enrollees and 1.2 million PDP enrollees, will have their plan terminated at the end of 2026. An additional 1.4 million Medicare Advantage enrollees are in a plan that is consolidating with another plan offered by the same insurer.

Medicine has its maps: Anatomists charted the body, and the Human Genome Project gave us the code. Now, the Human Cell Atlas, a global effort involving thousands of scientists, is using AI to create comprehensive reference maps of all human cells to understand human health and diagnose, monitor and treat disease. Given the extraordinary implications for drug discovery and potential cures, Chip talks with Dr. Sarah Teichmann, co-founder of the Human Cell Atlas, chair in Stem Cell Medicine at the University of Cambridge, and a non-executive director at 10x Genomics, among other roles, about the potential of the Human Cell Atlas.

More than half (53%) of reproductive-age women living in states with abortion-provision bans say they would not know where to go or where to find information if they needed an abortion, up from 43% in 2024, according to a new KFF survey.

This brief provides national estimates from the 2026 KFF Women’s Health Survey on reproductive age women’s experiences with abortion, the impact of Dobbs on abortion access and women’s concerns about future pregnancies, as well as women’s knowledge on the availability of medication abortion.

This tracker examines Executive Actions taken by the Trump administration that have the potential to impact LGBTQ+ people’s health. It lists the action taken by date, provisions relevant to LGBTQ+ health, and describes potential impact, including litigation challenging these actions.

A new KFF tracker highlights key federal policy actions during President Trump’s second term that concern issues related to mental health and substance use. The second Trump administration has emphasized law-and-order strategies and scaled back several mental health and substance use-related services, while also continuing some treatment-focused initiatives. The tracker can be viewed in multiple ways, including chronological order of policy actions and by category (Mental Health; Opioids/Substance Use Disorder; Federal Infrastructure/ Data/Guidance; and Gun Violence).

This chart collection compares the United States and other similarly large and wealthy nations across various measures of care quality to show how the U.S. stacks up against its peers and how that has changed over time.

This data note summarizes recent KFF polling on Americans’ experiences with health care costs, which factor into decisions about insurance coverage and care seeking and consistently ranks as a top financial worry for adults and their families.

This analysis examines the $500 checks that the Trump administration is sending to some Affordable Care Act Marketplace enrollees and the user fees that are paying for them. The checks are going to about 1 million enrollees in the 30 states that rely on the federal HealthCare.gov Marketplace who are not receiving any tax credits this year – a small share of the 19.2 million people who were enrolled nationally as of February.

In light of the uncertainty surrounding how states will verify the Medicaid medical frailty exclusion, this issue brief describes how the Supplemental Nutrition Assistance Program (SNAP) has handled similar administrative challenges.

This chart collection explores how much health spending is expected to grow in the coming years, with a look at growth in prescription drug spending, out-of-pocket spending, and related trends.

KFF’s recently released Tracking Poll finds that public confidence in the safety of COVID-19 vaccines for use during pregnancy has fallen, and many are uncertain about a false claim linking the vaccines with higher risk of miscarriage. Separately, conversations about childhood vaccines frame vaccination as an individual parental decision.

This is the 28th Employer Health Benefits Survey (EHBS) and reflects employer-sponsored health benefits in 2026. As in years past, the survey examines trends in employer coverage, including premiums, employee contributions, deductibles, offer rates, and employer practices. This year, we asked employers detailed questions about satisfaction with their health plans; coverage of GLP-1 agonists and IVF; actions taken in response to projected cost increases; and firms’ ability to obtain information about health care costs and utilization.

Workers are paying on average $7,471 annually toward the premiums for employer-sponsored family health benefits this year, which is up 9%, or $621, from 2025, per KFF’s annual benchmark health benefits survey of large and small employers. The burden of family premiums hits particularly hard for workers at small firms with less than 200 workers.

Since 1999, the Employer Health Benefits Survey has documented trends in employer-sponsored health insurance. Every year, private and non-federal public employers with 10 or more employees complete the survey.